Brief: Abogen Announces Licensing And Option Agreement With Novartis
02/10/2026 08:02
BRIEF-Abogen Announces Licensing And Option Agreement With Novartis Oct 2 (Reuters) - ABOGEN:
ABOGEN ANNOUNCES LICENSING AND OPTION AGREEMENT WITH NOVARTIS TO ADVANCE MRNA-ENCODED T-CELL ENGAGER AND OTHER POTENTIAL RNA PROGRAMS
ABOGEN - ABOGEN IS ELIGIBLE TO RECEIVE UP TO APPROXIMATELY USD 7.2 BILLION IN POTENTIAL MILESTONE PAYMENTS
ABOGEN - ABOGEN WILL RECEIVE AN UPFRONT PAYMENT OF USD 575 MILLION
Source text: ID:nPn8P923Ya
Further company coverage: NOVN.S
((Reuters.briefs@thomsonreuters.com;))
Recent news on Novartis AG
See all newsEurope Research Roundup: Ambu, Intesa Sanpaolo, Solvay
Swiss pharma industry behind in technology and clinical trials, index shows
European shares rise as Democrats take US Congress, Novo Nordisk surges
European shares rise as Democratic sweep lifts clean energy, bank stocks
Europe set to open lower as Democratic sweep fuels AI regulation fears